| 134.2 0.03 (0.02%) | 07-29 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 157.04 | 1-year : | 183.43 |
| Resists | First : | 134.46 | Second : | 157.04 |
| Pivot price | 134.06 |
|||
| Supports | First : | 133.27 |
Second : | 132.55 |
| MAs | MA(5) : | 134.23 |
MA(20) : | 133.84 |
| MA(100) : | 95.98 |
MA(250) : | 73.32 |
|
| MACD | MACD : | 5.8 |
Signal : | 7.5 |
| %K %D | K(14,3) : | 80.2 |
D(3) : | 84.7 |
| RSI | RSI(14): 79.8 |
|||
| 52-week | High : | 134.46 | Low : | 34.34 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ APGE ] has closed below upper band by 34.8%. Bollinger Bands are 95.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 12 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 134.37 - 135.03 | 135.03 - 135.7 |
| Low: | 132.48 - 133.18 | 133.18 - 133.89 |
| Close: | 133.09 - 134.18 | 134.18 - 135.3 |
Apogee Therapeutics, Inc. is a biotechnology firm, operating via its subsidiary, dedicated to advancing biologic treatments for conditions such as atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and a range of other inflammatory and immunological disorders. Its primary focus includes APG777, a subcutaneous (SQ) monoclonal antibody (mAb) engineered for an extended half-life to treat AD, and APG808, a similarly formulated SQ extended half-life mAb targeting COPD. Furthermore, its earlier-stage pipeline features APG990, another SQ extended half-life mAb designed for AD, and APG222, comprising extended half-life subcutaneous antibodies also aimed at AD. Established in 2022, the company maintains its headquarters in Waltham, Massachusetts.
Tue, 28 Jul 2026
Is Apogee Therapeutics Inc. (APGE) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Mon, 27 Jul 2026
Apogee Therapeutics Inc (APGE) Valuation: PE, PB & Fair Value Analysis - tradingkey.com
Sat, 25 Jul 2026
Apogee Therapeutics Inc (APGE) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
Sat, 25 Jul 2026
Form 4 Apogee Therapeutics Inc For: 24 July By Investing.com - Investing.com South Africa
Fri, 24 Jul 2026
Form 4 Apogee Therapeutics Inc For: 24 July By Investing.com - Investing.com Canada
Fri, 24 Jul 2026
Apogee Therapeutics (APGE) CFO makes bona fide gift of 15,000 shares - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 62 (M) |
| Shares Float | 59 (M) |
| Held by Insiders | 2.3 (%) |
| Held by Institutions | 109.2 (%) |
| Shares Short | 4,130 (K) |
| Shares Short P.Month | 10,480 (K) |
| EPS | -4.33 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 16.87 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -19 % |
| Return on Equity (ttm) | -28.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -4.89 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -235 (M) |
| Levered Free Cash Flow | -143 (M) |
| PE Ratio | -31.07 |
| PEG Ratio | 0 |
| Price to Book value | 7.95 |
| Price to Sales | 0 |
| Price to Cash Flow | -35.56 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|